Volume 18, Issue 4

Dear IBD Colleagues and Friends, Warm greetings from the ECCO News Team! This year, the entire ECCO Team has again worked hard to organise a top quality meeting, which will take place in the inclusive and welcoming city of Stockholm, home of environmental sustainability! Therefore, we would like to invite all of you to the 19th Congress of ECCO, to be held from February 21 to 24, 2024.

The conducted research had two aims: Aim 1: To characterise the inter-/intra-individual composition of the mycobiome of patients with IBD and healthy controls utilising a variety of sample types and methodological techniques. Aim 2: To provide a large dataset of fungal internal transcribed spacer (ITS) rRNA sequencing data to complement the bacterial 16S rRNA analysis underway in-house.

To evaluate the in vitro effect of selected novel matrix-derived peptides (matrikines) that specifically appear in the intestinal tissue of patients with Crohn’s Disease (CD) fibrostenosis on primary human intestinal myofibroblasts (iMFBs).

This project aimed to understand the effects that crucial IBD epithelial stress factors (i.e. ATG16L1 and XBP1 impairments) might have in enteric fibroblasts and neurons.

Multiple patient, disease and pharmacokinetic (including anti-TNF drug and antibody concentrations) factors, as well as a limited number of proteomic markers, have been implicated in anti-TNF treatment failure. However, their relative effects and interactions have not been fully explored. We aimed to replicate previously postulated serological markers and to identify novel inflammatory and immune response proteomic markers related to anti-TNF treatment failure in patients with active luminal Crohn’s Disease.